Avalyn Pharma director Meyer reports no holdings

Avalyn Pharma director Robert J. Meyer filed an initial Form 3 showing no reportable holdings or transactions.

Rhea-AI Filing Summary

Avalyn Pharma Inc. (AVLN) filed an initial statement of beneficial ownership for Robert J. Meyer, who is identified as a director of the company. The filing reports no securities transactions and no reportable holdings or derivative positions at the time of this Form 3.

Key Figures

Reported transactions: 0 transactions Reported securities holdings: 0 shares Reported derivative positions: 0 positions

3 metrics

Reported transactions 0 transactions Total transactions reported in Robert J. Meyer’s initial Form 3

Reported securities holdings 0 shares Reportable securities held by Robert J. Meyer at time of Form 3

Reported derivative positions 0 positions Derivative securities positions reported for Robert J. Meyer in Form 3

Key Terms

Power of Attorney

1 terms

Power of Attorney regulatory

"Exhibit 24 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing report for Avalyn Pharma Inc. (AVLN)?

It reports that Robert J. Meyer is a director of Avalyn Pharma Inc. and that there are no reportable securities holdings or derivative positions and no transactions disclosed in this initial statement of beneficial ownership.

Does the Avalyn Pharma (AVLN) Form 3 show any stock ownership by Robert J. Meyer?

No. The Form 3 for Avalyn Pharma Inc. lists no reportable securities holdings for director Robert J. Meyer at the time of the filing, and it also shows no derivative positions reported.

Are there any buy or sell transactions disclosed in this AVLN Form 3?

No. The Form 3 for Avalyn Pharma Inc. shows no reported purchase or sale transactions by director Robert J. Meyer. All transaction counts, including buys, sells, exercises, and gifts, are reported as zero in this initial filing.

Does the Avalyn Pharma (AVLN) Form 3 indicate use of a Rule 10b5-1 trading plan?

No. The available information for this Form 3 does not indicate that any transactions were made under a Rule 10b5-1 trading plan, and in any case, no transactions are reported for Robert J. Meyer.

What role does Robert J. Meyer have at Avalyn Pharma Inc. (AVLN) according to the Form 3?

According to the Form 3, Robert J. Meyer is reported as a director of Avalyn Pharma Inc. He is not identified as an officer or ten percent owner in this filing, and no other roles are listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:06 PM Accepted by SEC EDGAR 09/17/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Meyer Robert J.

(Last) (First) (Middle)

C/O AVALYN PHARMA INC.

105 W FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/15/2026

3. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Douglas Carlson, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)